Bright Minds Biosciences Inc. - common stock (NQ:DRUG)

60.47 +1.88 (+3.21%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 24, 2025 Add to My Watchlist

Price and Volume

Volume	89,988
Open	59.05
Bid (Size)	49.00 (100)
Ask (Size)	65.00 (300)
Prev. Close	58.59
Today's Range	59.00 - 60.89
52wk Range	23.18 - 70.23
Shares Outstanding	11,834,361
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Why Bright Minds Biosciences Stock Topped the Market on Monday ↗

November 17, 2025

The company isn't wasting any time drafting seasoned professionals to help it develop medication for a rare genetic disorder.

Via The Motley Fool

Large Patient Population Is Key Driver For Bright Minds' Growth ↗

September 08, 2025

BTIG initiates coverage on Bright Minds Biosciences with a Buy rating, citing BMB‑101's potential and key Phase 2 data expected by the end of 2025

Via Benzinga

Performance

YTD	+47.1%	+47.1%
1 Month	+2.9%	+2.9%
3 Month	+45.0%	+45.0%
6 Month	+120.4%	+120.4%
1 Year	+56.7%	+56.7%

More News

Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upside ↗

May 07, 2025

Via Benzinga

Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research

March 04, 2025

From Bright Minds Biosciences

Via GlobeNewswire

Bright Minds Biosciences to Participate at Three Healthcare Conferences in March

February 24, 2025

From Bright Minds Biosciences

Via GlobeNewswire

Biotechs on the Brink: 2 Stocks With Huge Potential

February 14, 2025

Via MarketBeat

This Prudential Financial Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday ↗

January 23, 2025

Via Benzinga

Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer

January 07, 2025

From Bright Minds Biosciences

Via GlobeNewswire

Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting

November 21, 2024

From Bright Minds Biosciences

Via GlobeNewswire

Meet the Biotech Stock That Has Generated Nvidia-Like Returns in Less Than a Month ↗

November 13, 2024

Via The Motley Fool

Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement

November 04, 2024

From Bright Minds Biosciences

Via GlobeNewswire

EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank? ↗

November 04, 2024

Via Benzinga

What's Going On With Bright Minds Biosciences Stock? ↗

October 21, 2024

Via Benzinga

Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data

October 21, 2024

From Bright Minds Biosciences

Via GlobeNewswire

MarketBeat Week in Review – 10/14 - 10/18

October 19, 2024

Via MarketBeat

Crude Oil Down Over 1%; American Express Shares Fall After Q3 Results ↗

October 18, 2024

Via Benzinga

What's Going On With Bright Minds Biosciences Stock Friday? ↗

October 18, 2024

Via Benzinga

Dow Falls Over 100 Points; Netflix Posts Upbeat Results ↗

October 18, 2024

Via Benzinga

Firefly Neuroscience And Bright Minds Advance Phase 1 Study With AI-Driven Data Analysis ↗

October 17, 2024

Via Benzinga

Bright Minds Biosciences (NASDAQ: DRUG) Soars 1800% Amid Short Squeeze Alongside PRSO, ILLR and NIVF

October 16, 2024

Via AB Newswire

Dow Jumps 250 Points; U.S. Bancorp Earnings Top Views ↗

October 16, 2024

Via Benzinga

Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models

October 16, 2024

From Bright Minds Biosciences

Via GlobeNewswire

US Stocks Mixed; Abbott Reports Better-Than-Expected Q3 Results ↗

October 16, 2024

Via Benzinga

Bright Minds Biosciences Stock Surges Almost 1,500%

October 16, 2024

Via MarketBeat

Why Ericsson Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket ↗

October 15, 2024

Via Benzinga

Frequently Asked Questions

Is Bright Minds Biosciences Inc. - common stock publicly traded?

Yes, Bright Minds Biosciences Inc. - common stock is publicly traded.

What exchange does Bright Minds Biosciences Inc. - common stock trade on?

Bright Minds Biosciences Inc. - common stock trades on the Nasdaq Stock Market

What is the ticker symbol for Bright Minds Biosciences Inc. - common stock?

The ticker symbol for Bright Minds Biosciences Inc. - common stock is DRUG on the Nasdaq Stock Market

What is the current price of Bright Minds Biosciences Inc. - common stock?

The current price of Bright Minds Biosciences Inc. - common stock is 60.47

When was Bright Minds Biosciences Inc. - common stock last traded?

The last trade of Bright Minds Biosciences Inc. - common stock was at 11/24/25 04:00 PM ET

What is the market capitalization of Bright Minds Biosciences Inc. - common stock?

The market capitalization of Bright Minds Biosciences Inc. - common stock is 715.62M

How many shares of Bright Minds Biosciences Inc. - common stock are outstanding?

Bright Minds Biosciences Inc. - common stock has 716M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.